MBX Biosciences Closes $34.6 Million Series A Financing in Rare Endocrine Diseases

Retrieved on: 2020-07-26 20:00:00

Tags for this article:

Click the tags to see associated articles and topics

MBX Biosciences Closes $34.6 Million Series A Financing in Rare Endocrine Diseases. View article details on hiswai:

Excerpt

<div>The financing was led by Frazier Healthcare Partners, with participation from OrbiMed, <b>New Enterprise Associates</b>, Indiana Philanthropic Venture ...</div>

Article found on:

View Original Article